DrugPatentWatch Database Preview
Profile for European Patent Office Patent: 1261586
» See Plans and Pricing
Country | SPC | SPC Expiration |
---|---|---|
France | 10C0010 | Start Trial |
Sweden | 1290013-0 | Start Trial |
France | 12C0028 | Start Trial |
Italy | 132012902044560 | Start Trial |
Austria | 15/2012 | Start Trial |
Belgium | 2010C/008 | Start Trial |
Belgium | 2012C/016 | Start Trial |
US Patent Family Members and Approved Drugs for European Patent Office Patent: 1261586
US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
---|---|---|---|---|
Start Trial | Jul 31, 2023 | Astrazeneca Ab | KOMBIGLYZE XR | metformin hydrochloride; saxagliptin hydrochloride |
Start Trial | Jul 31, 2023 | Astrazeneca Ab | QTERNMET XR | dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride |
Start Trial | Jul 31, 2023 | Astrazeneca Ab | ONGLYZA | saxagliptin hydrochloride |
Start Trial | Jul 31, 2023 | Astrazeneca Ab | QTERN | dapagliflozin; saxagliptin hydrochloride |
>US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |